Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Blast Crisis 1

Interventions

Temozolomide 14Radiotherapy 14Carboplatin 7Irinotecan 6Everolimus 5Filgrastim 4Carmustine 4Surgical Procedures, Operative 3Radiation 3Paclitaxel 3Ifosfamide 3selpercatinib 2pembrolizumab 2Trastuzumab 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Methotrexate 2Imatinib Mesylate 2IL13-PE38 2Dasatinib 2Chemotherapy, Adjuvant 2Bevacizumab 2vitespin 1veliparib 1vatalanib 1transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1tipifarnib 1terameprocol 1temsirolimus 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Central Nervous System Neoplasms × vatalanib × Clear all
NCT00128700 2012-09-24

Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

European Organisation for Research and Treatment of Cancer - EORTC

Phase 1/2 Completed
20 enrolled
CNSSarcoma

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡